Chemistry:CPHPC

From HandWiki
CPHPC
CPHPC.png
Names
Preferred IUPAC name
(2R,2′R)-1,1′-Hexanedioyldi(pyrrolidine-2-carboxylic acid)
Other names
Ro 63-8695
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
Properties
C16H24N2O6
Molar mass 340.37 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is ☑Y☒N ?)
Infobox references
Tracking categories (test):

CPHPC ((R)-1-{6-[(R)-2-carboxypyrrolidin-1-yl]-6-oxohexanoyl}pyrrolidine-2-carboxylic acid) is a proline-derived small molecule able to strip amyloid P (AP) from deposits by reducing levels of circulating serum amyloid P (SAP). The SAP-amyloid association has also been identified as a possible drug target for anti-amyloid therapy, with the recent development and first stage clinical trials of CPHPC for amyloidosis.[1]

CPHPC has also been patented for possible treatment of Alzheimer's disease.[2]

Mechanism

The symmetrical nature of CPHPC allows it to bind to two molecules of AP (the SAP subunits). This allows five molecules of CPHPC to bind two SAP pentamers together by the B/binding face blocking the binding on to existing amyloid deposits.[3]

References

  1. "Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis". Nature 417 (6886): 254–9. 2002. doi:10.1038/417254a. PMID 12015594. Bibcode2002Natur.417..254P. 
  2. Dinh, Steven & Ihor Shevchuk, "Pharmaceutical Formulations for the Treatment of Alzheimer's Disease", WO patent 2008014232
  3. Reducing the Supply of Amyloid Fibril Precursor Proteins, MedScape Today